-+ 0.00%
-+ 0.00%
-+ 0.00%

BiomX To Present Phase 1b/2a Clinical Trial Data For BX004 At The ERS Congress 2024

Benzinga·09/03/2024 12:23:12
Listen to the news

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented as a poster at the European Respiratory Society (ERS) Congress in Vienna, Austria taking place September 7-11, 2024. The poster will be presented on Monday, September 9, 2024, 8:00AM – 9:30AM local time, at Poster Session 234: "Navigating the journey of adult cystic fibrosis: past and future perspectives" (Room PS-21; Board Number 2, Poster ID 2341).

The poster, titled "Novel nebulized phage cocktail in CF patients with chronic P. aeruginosa pulmonary infection: a Ph1b/2a randomized, double-blind, placebo-controlled trial," reports that the Company's phage cocktail, BX004-A, demonstrated favorable safety and notable microbiologic and clinical efficacy in cystic fibrosis patients with chronic P. aeruginosa pulmonary infections, including in patients on standard of care treatment of elexacaftor / tezacaftor / ivacaftor (ETI). The poster will be available on the Company's website following the poster session.